Novel injectable alginate biomaterial attenuates progressive infarct expansion and preserves left ventricular systolic and diastolic function late after myocardial infarction

N Landa, MS Feinberg, R Holbova, L Miller, S Cohen, J Leor

Research output: Contribution to journalMeeting Abstractpeer-review

Abstract

Cessation or reversal of progressive left ventricular (LV) dysfunction is a major aim of heart failure therapy. We developed a cross-linked concentrated alginate solution, which upon solidification in tissue becomes a hydrogel. The aim of the present study was to test the hypothesis that an injection of this novel alginate solution mimicking the extracellular matrix (ECM) into an old scar tissue, late after myocardial infarction (MI), will provide physical and biological scaffolding, will promote tissue rejuvenation and will prevent progressive LV dysfunction.
Original languageEnglish
Pages (from-to)73A-74A
JournalJournal of the American College of Cardiology
Volume47
Issue number4
StatePublished - 21 Feb 2006

Fingerprint

Dive into the research topics of 'Novel injectable alginate biomaterial attenuates progressive infarct expansion and preserves left ventricular systolic and diastolic function late after myocardial infarction'. Together they form a unique fingerprint.

Cite this